Aurinia Pharmaceuticals
Stock Forecast, Prediction & Price Target
Aurinia Pharmaceuticals Financial Estimates
Aurinia Pharmaceuticals Revenue Estimates
Aurinia Pharmaceuticals EBITDA Estimates
Aurinia Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $45.60M N/A | $134.03M 193.89% | $175.51M 30.95% | Avg: $282.30M Low: $261.54M High: $308.02M avg. 60.84% | Avg: $349.52M Low: $323.95M High: $375.75M avg. 23.81% | Avg: $393.19M Low: $364.41M High: $422.68M avg. 12.49% | Avg: $449.35M Low: $416.47M High: $483.06M avg. 14.28% |
Net Income
% change YoY
| $-180.96M N/A | $-108.18M 40.22% | $-78.02M 27.87% | Avg: $71.19M Low: $31.51M High: $114.58M avg. 191.24% | Avg: $133.20M Low: $63.02M High: $181.90M avg. 87.10% | Avg: $168.30M Low: $152.29M High: $184.71M avg. 26.35% | Avg: $200.53M Low: $181.45M High: $220.08M avg. 19.14% |
EBITDA
% change YoY
| $-178.63M N/A | $-111.47M 37.59% | $-63.04M 43.44% | Avg: $-239.39M Low: $-261.20M High: $-221.78M avg. -279.71% | Avg: $-296.40M Low: $-318.63M High: $-274.70M avg. -23.81% | Avg: $-333.42M Low: $-358.44M High: $-309.02M avg. -12.49% | Avg: $-381.05M Low: $-409.64M High: $-353.17M avg. -14.28% |
EPS
% change YoY
| -$1.4 N/A | -$0.76 45.71% | -$0.54 28.94% | Avg: $0.47 Low: $0.22 High: $0.8 avg. 187.65% | Avg: $0.89 Low: $0.44 High: $1.27 avg. 86.97% | Avg: $1.18 Low: $1.06 High: $1.29 avg. 32.76% | Avg: $1.4 Low: $1.27 High: $1.54 avg. 19.14% |
Operating Expenses
% change YoY
| $225.24M N/A | $239.83M 6.47% | $253.05M 5.51% | Avg: $4.39B Low: $4.07B High: $4.80B avg. 1638.47% | Avg: $5.44B Low: $5.04B High: $5.85B avg. 23.81% | Avg: $6.12B Low: $5.67B High: $6.58B avg. 12.49% | Avg: $7.00B Low: $6.49B High: $7.52B avg. 14.28% |
FAQ
What is Aurinia Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 80.96% in 2025-2028.
We have gathered data from 5 analysts. Their low estimate is 31.51M, average is 71.19M and high is 114.58M.
What is Aurinia Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 27.85% in 2025-2028.
We have gathered data from 5 analysts. Their low revenue estimate is $261.54M, average is $282.30M and high is $308.02M.
What is Aurinia Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 81.63% in 2025-2028.
We have gathered data from 5 analysts. Their low earnings per share estimate is $0.22, average is $0.47 and high is $0.8.